In addition to his role with Neurexis, Dr. Bayer is a Professor in the Department of Pharmacology at the University of Colorado – Anschutz Medical Campus.
Dr. Bayer is the inventor of the tatCN19o peptide. His research interests include: Elucidating the molecular mechanisms underlying learning, memory and cognition; Applying fundamental neuroscience findings to better understand neurological disorders such as Alzheimer’s disease, Down syndrome, schizophrenia and addiction; Pursuing advances in neuroprotection after acute injuries such as stroke and global cerebral ischemia.
He conducted his Postdoctoral Fellowship in Neuroscience, Biochemistry and Cell Biology at Stanford University School of Medicine and earned his PhD in Molecular Biology from the Heinrich Pette Institute, Hamburg University.
Sign up to view 0 direct reports
Get started
This person is not in any teams